Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Feb 4;10(2):99. doi: 10.1038/s41419-019-1371-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — ABCB1 is responsible for CHD1L-induced NSCLC cell cisplatin resistance. a Five genes, ABCB1, CYP2C19, SULT1E1, ERCC3, and GSTP1 were found to have at least a 2-fold mRNA differential expression in A549-CHD1L cells compared to that in A549-vec using Cancer Drug Resistance RT 2 Profiler™ PCR Array. b Expression of ABCB1, CYP2C19, SULT1E1, ERCC3, and GSTP1 verified in A549-CHD1L and respective control by western blot. c Overexpression of CHD1L and ABCB1 was examined by immunohistochemistry in NSCLC tissues; scale bar, 10 μm, original magnification, ×200. d Silencing of ABCB1 in combination with cisplatin caused a marked inhibition of proliferation in A549-CHD1L cells. e Annexin-V-FITC/PI dual staining assay show that the enhanced cisplatin-resistance ability in A549-CHD1L cells was inhibited by silencing of ABCB1. f Western blot analysis showed that the cisplatin induced γ-H2AX over-expression could be rescued by silencing ABCB1 in CHD1L-overexpressing NSCLC cells. g Images of xenograft tumors harvested at the end of the experiment. h Growth curves of tumor xenografts. i The weights of tumors are presented as a Cleveland dot plot, and the average± S.D. is included (n=6/group; **P<0.01; ***P<0.001; NS, no significance)